doi: 10.1161/01.RES.0000129178.56294.17
© 2004 American Heart Association, Inc.
Reviews |
Caveolae and Caveolins in the Cardiovascular System
From the Laboratory of Endothelial Cell Biology (J.-P.G.), Institut de Recherches Cliniques de Montreal (IRCM), Canada, and the Department of Pharmacology and Program in Vascular Cell Signaling and Therapeutics (P.B., W.C.S.), Boyer Center for Molecular Medicine, Yale University School of Medicine, New Haven, Conn.
Correspondence to Dr. William C. Sessa, Yale University School of Medicine, Boyer Center for Molecular Medicine, 295 Congress Avenue, New Haven CT 06536-0812. E-mail william.sessa{at}yale.edu
 |
Abstract |
|---|
 Top Abstract IntroductionEndothelium: Paradigm Shift From...Caveolae and Signal TransductionRole for Caveolae in...Caveolin-1Endothelial Nitric Oxide...MechanotransductionTyrosine Kinases and Signaling...Caveolins and EC FunctionsCaveolins and VSM FunctionCaveolin-1 and AtherosclerosisCaveolins and Myocardial...ConclusionsReferences |
|---|
Caveolae and the caveolae coat proteins, caveolins, are putatively implicated in many cellular processes, including transcytosis of macromolecules, cholesterol transport, and signal transduction. Recent insights into the physiological and pathophysiological roles of these organelles and the caveolins from genetically modified mice suggest that they may be profoundly important for postnatal cardiovascular function, including endothelial barrier function, regulation of nitric oxide synthesis, cholesterol metabolism, and cardiac function.
Key Words: caveolae • caveolins • signaling • phenotypes • nitric oxide
|
Introduction |
|---|
|
TopAbstractIntroductionEndothelium: Paradigm Shift From...Caveolae and Signal TransductionRole for Caveolae in...Caveolin-1Endothelial Nitric Oxide...MechanotransductionTyrosine Kinases and Signaling...Caveolins and EC FunctionsCaveolins and VSM FunctionCaveolin-1 and AtherosclerosisCaveolins and Myocardial...ConclusionsReferences |
|---|
Caveolae (ie, "small caves") are 50- to 100-nm (diameter) vesicles found throughout the various cell types of the body. These organelles, discovered >50 years ago, have been and continue to be fertile grounds for discoveries as well as interesting controversies. Many recent reviews have outlined the nature of caveolae structures, regulation of caveolae and less well-defined lipid rafts, generalized signaling mechanisms in or out of caveolae, and their roles in physiology and pathophysiology.1–5 Therefore, the main focus of this review is to outline the role of caveolae and the caveolins in cardiovascular cells and to highlight new insights into the functions of caveolae and caveolins.
|
Endothelium: Paradigm Shift From Cellophane Liners to Bags Full of Caveolae? |
|---|
|
TopAbstractIntroductionEndothelium: Paradigm Shift From...Caveolae and Signal TransductionRole for Caveolae in...Caveolin-1Endothelial Nitric Oxide...MechanotransductionTyrosine Kinases and Signaling...Caveolins and EC FunctionsCaveolins and VSM FunctionCaveolin-1 and AtherosclerosisCaveolins and Myocardial...ConclusionsReferences |
|---|
Paradigm shifts in vascular biology, spearheaded by electron microscopy and culturing of vascular endothelial and smooth muscle cells, led to the present explosion of information regarding the dynamic nature of vascular cells. These discoveries combined with basic cellular biology identifying molecular zip codes for protein trafficking and scaffolding molecules that regionally regulate protein–protein interactions has influenced many investigators to incorporate temporally and spatially restricted signaling events into vascular physiology. At the same time, the identification of caveolins as the major coat proteins of caveolae has sparked research into the roles and function of caveolae and have stimulated the fertile ground of understanding signal transduction in cholesterol-rich microdomain platforms such as caveolae. Although there are ample data and reviews supporting this view, "not all that gleams is gold" because there are many unanswered questions regarding the nature and function of caveolae.
It is clear that the major plasmalemma vesicle structure in endothelial cells (ECs) are caveolae as opposed to clathrin-coated vesicles. The number of caveolae is high in continuous endothelium and low in fenestrated or discontinuous endothelium. Based on electron microscopy data, caveolae can exist luminally and abluminally, with the largest number in perijunctional zones between endothelia.1 This close apposition of caveolae to intercellular junctions may give rise to the conclusion that certain junctional molecules may colocalize with caveolin-1 by immunofluorescence microscopy. In addition to caveolae, there are racemose caveolin-1–positive structures in postcapillary venules termed vesiculo-vascuolar vesicles (VVOs) that are most likely fused caveolae.6 These VVOs may participate in perijunctional transcytosis of macromolecules; however, this is somewhat controversial. One issue often unappreciated is that caveolae number, quantified by electron microscopy, decreases 10- to 1000-fold in ECs in culture (0.1 to 9 per µm2 of plasma membrane)7–10 compared with the endothelium in vivo (78 to 89 per µm2 in continuous endothelium with less caveolae in the blood–brain barrier),1,11,12 although ample caveolin-1 protein expression is detected in cultured cells. Despite these caveats, recent insights into the dynamics of caveolae trafficking in cultured cells has led to the discovery of internalized caveolae or "caveosomes" as unique entities distinct from lysosomes,13–15 whereas others argue caveolae are static structures that do not move.16,17 Finally, because caveolae are distinct on electron microscopy but lipid rafts are not, the existence of cholesterol-rich raft domains that organize signaling systems in living cells has recently been challenged.2
|
Caveolae and Signal Transduction |
|---|
|
TopAbstractIntroductionEndothelium: Paradigm Shift From...Caveolae and Signal TransductionRole for Caveolae in...Caveolin-1Endothelial Nitric Oxide...MechanotransductionTyrosine Kinases and Signaling...Caveolins and EC FunctionsCaveolins and VSM FunctionCaveolin-1 and AtherosclerosisCaveolins and Myocardial...ConclusionsReferences |
|---|
General Considerations
There is emerging evidence supporting compartmentalization of signaling systems. As previously stated, "molecular zip codes" can determine the targeting of specific proteins to the nucleus, Golgi complex, mitochondria, and plasma membrane. Specific targeting coupled with the growing numbers of stimulus-dependent protein–protein interactions composed of receptors, kinases/phosphatases, scaffolding proteins, and molecular chaperones are logical mechanisms to ensure specificity of signaling, at the same time permitting similar pathways to exist in different parts of the same cell (Figure). Caveolae and lipid rafts are an attractive way to segregate or integrate certain pathways in microdomains of the plasma membrane. However, it is our opinion that it is erroneous to conclude that all signaling takes place in these organelles despite biochemical evidence in isolated caveolae/rafts, because all enrichment/purification schemes for caveolae/rafts have significant methodological concerns.2,18 More importantly, caveolin-1, -2, and -3 knockout mice are viable arguing against an essential role for the organelles19 and cholesterol-disrupting drugs, a standard approach to rule in or out caveolae or lipid rafts in given pathways, likely do more than just extract caveolae/raft domain cholesterol and change plasma membrane fluidity and permeability.2
|
However, to err on the side of caution, many of the observations of signaling pathways discovered in caveolin-1 enriched domains or rafts, may be caused by the diverse operational definitions of caveolae-dependent signaling. Several or all criteria for signaling in caveolae used by most investigators include: colocalization of a given protein with caveolin-1, electron microscopic colabeling with caveolin-1, cholesterol-sensitive signaling (ie, increase or decrease in effect when cells are exposed to cholesterol depleting agents, ß-methyl cyclodextrin or oxidizing agents, cholesterol oxidase), hydrodynamic cosedimentation of proteins with caveolin-1 in sucrose gradients using detergent-free systems, detergent-insoluble membranes, sodium carbonate-resistant membranes, or isolated plasmalemma caveolae by colloidal silica.20–24 The strengths and caveats of all of these methods are hopefully obvious and may have been responsible for the explosion of molecules found in caveolin-enriched microdomains or rafts. One salient illustration supporting the problem with an operational definition of a caveolin-enriched membrane or a raft is exemplified by recent use of proteomics to identify "lipid raft" proteins using the criterion of Triton X-100–resistant membranes in T cells or HeLa cells.18,25 In the latter cell type, the additional criterion of ß-methyl cyclodextrin sensitivity was used to distinguish detergent-resistant proteins from cholesterol-sensitive proteins. In both circumstances, many predicted proteins were found, including flotillin and G proteins; however, many cytoskeletal proteins, heat-shock proteins, resident proteins of the endoplasmic reticulum, nucleus, or mitochondria were found in detergent- or sodium carbonate-treated membranes. In HeLa cells, it was estimated that one-third of the detergent-resistant proteins and two-thirds of the sodium carbonate-resistant proteins were "nonraft proteins," thus implying that many of the proteins "in or out" of rafts are most likely artifactually generated by these procedures. An alternative, less likely explanation is that rafts are everywhere in the cell and all these proteins are embedded in cholesterol-rich domains; however, this view is not compatible with the known facts about cholesterol synthesis and trafficking in cells. Neither study attempted to dissect proteins in caveolae versus rafts; however, with the availability of cell lines and mice deficient in caveolins/ caveolae, and the technical breakthrough of quantitative proteomics, work in the next several years will clearly delineate which proteins and signaling pathways are "in or out" of caveolae in a more definitive manner.
With these caveats in mind, a growing body of evidence suggests that caveolae may act as transducers or membrane-delimited sites of signal transduction. Isolation and purification of caveolin-enriched microdomains from tissues and cultured cells reveal that they contain surprisingly high levels of several intracellular signaling proteins and tyrosine phosphorylated proteins.26 It is thereby plausible that targeted concentrations of preassembled signaling complexes exist or can be assembled via receptor-dependent signaling events.
|
Role for Caveolae in EC Signaling |
|---|
|
TopAbstractIntroductionEndothelium: Paradigm Shift From...Caveolae and Signal TransductionRole for Caveolae in...Caveolin-1Endothelial Nitric Oxide...MechanotransductionTyrosine Kinases and Signaling...Caveolins and EC FunctionsCaveolins and VSM FunctionCaveolin-1 and AtherosclerosisCaveolins and Myocardial...ConclusionsReferences |
|---|
Because of their high abundance in ECs, caveolae have been implicated in the regulation of many functions including macromolecular transport in the microcirculation. Recent reviews have addressed the cell biological considerations of caveolae-type organelles in transport27,28 and perhaps drug delivery;29 therefore, we focus on the evidence supporting the role of caveolae in signaling. An important conceptual hurdle in discussing the role of caveolae in signaling is to separate signaling regulated by the putative movement of proteins in or out of caveolae from processes regulated by caveolae-mediated endocytosis (typically interpreted through fractionation experiments and cholesterol disrupting agents), with pathways that may be regulated by direct or indirect interactions with caveolin-1 (typically determined by coprecipitation and in vitro binding experiments).
|
Caveolin-1 |
|---|
|
TopAbstractIntroductionEndothelium: Paradigm Shift From...Caveolae and Signal TransductionRole for Caveolae in...Caveolin-1Endothelial Nitric Oxide...MechanotransductionTyrosine Kinases and Signaling...Caveolins and EC FunctionsCaveolins and VSM FunctionCaveolin-1 and AtherosclerosisCaveolins and Myocardial...ConclusionsReferences |
|---|
Caveolin-1, the major coat protein responsible for caveolae assembly, itself may positively or negatively regulate signaling via direct or indirect protein–protein interactions with resident caveolar proteins. Alternatively, because caveolin-1 is essential for formation of the caveolae, stimuli that increase or decrease caveolin levels may regulate the number of caveolae and thus signaling. As reviewed previously,26,30 caveolin-1 interacts with itself to oligomerize in cells and can bind to additional proteins via its caveolin scaffolding domain (CSD) (residues 82 to 101 in caveolin-1) or carboxy tail.
Recent experiments suggest that caveolin proteins in ECs are themselves regulated by intracellular signaling events. Caveolin-1 can be phosphorylated on tyrosine 14 in response to oxidative31,32 and shear stress,33 likely by src family kinases.34 Interestingly, this phosphorylation site is thought to serve as a phosphotyrosine binding site for the recruitment of SH2 domain-containing molecules. Caveolin-2, an additional isoform found in ECs, is not essential for caveolae formation but regulates the number of caveolae in many cell systems. Recent evidence suggests that caveolin-2 can also be phosphorylated on tyrosine 19 by c-src35 and serine phosphorylated on serines 23 and 36,36 likely through the action of casein kinase 2. However, there are no data supporting that caveolin-2, per se, can modulate signaling in a manner similar to caveolin-1.
Caveolin-1 may also modulate signal transduction through the regulation of cholesterol efflux. Caveolin-1 can bind cholesterol37 and caveolin-1/caveolae may regulate the influx38,39 or efflux of cholesterol onto cholesterol acceptors such as low-density lipoprotein (LDL)40,41 and high-density lipoprotein.42 Plasmalemmal cholesterol, a key component of caveolae and lipid rafts, in turn, can regulate membrane fluidity and the rate of diffusion of many signaling molecules.
|
Endothelial Nitric Oxide Synthase |
|---|
|
TopAbstractIntroductionEndothelium: Paradigm Shift From...Caveolae and Signal TransductionRole for Caveolae in...Caveolin-1Endothelial Nitric Oxide...MechanotransductionTyrosine Kinases and Signaling...Caveolins and EC FunctionsCaveolins and VSM FunctionCaveolin-1 and AtherosclerosisCaveolins and Myocardial...ConclusionsReferences |
|---|
The contemporaneous identification of endothelial nitric oxide synthase (eNOS) in plasmalemmal caveolae of ECs by 2 laboratories43,44 has opened up insights into the capacity of caveolae-enriched molecules to participate in signal transduction. eNOS is the NOS isoform in EC that produces low levels of NO in response to mechanical forces and agonists such as acetylcholine, estrogen, bradykinin, or vascular endothelial growth factor (VEGF), and is the isoform that uniquely regulates many aspects of cardiovascular homeostasis. eNOS is a peripheral membrane protein by virtue of its molecular targeting (via cotranslational N-myristoylation and posttranslational cysteine palmitoylation45–47) to the cytoplasmic aspect of the Golgi complex and to caveolae/lipid rafts.48 eNOS can target to the Golgi and plasma membrane and isolated lipid rafts in a cyclodextrin-sensitive manner in model cell systems lacking caveolins/caveolae and is functionally active to produce basal and ionophore stimulated NO.49 The lack of importance of caveolin-1 and caveolae for the trafficking of eNOS is further illustrated in mice deficient in caveolin-1 where Ach-stimulated relaxations, cGMP accumulation, and NO-dependent microvascular leakage are largely enhanced, not reduced,50,51 clearly showing that caveolae are not essential for eNOS localization and activation using these specific mechanisms of activation. However, expression of caveolin-1 to induce caveolae, reminiscent of the situation in intact ECs, does not influence eNOS trafficking in live cells or enrichment of eNOS in cholesterol-rich, caveolin-1–containing domains, but negatively regulates NO synthesis.49 Collectively, these data in mice or cells lacking caveolae suggest that eNOS targeting to the Golgi and plasma membrane occurs in the absence of caveolins and caveolae, and caveolin-1 in caveolae is a negative regulator of eNOS function. However, because eNOS can be activated by diverse classes of stimuli (ie, shear stress, bioactive lipids, bradykinin, and VEGF), further experimentation is required to dissect the role of caveolae or caveolins, per se, in signal transmission. Previous studies demonstrated that localization of eNOS to caveolae was essential for eNOS activation.41,44,47,52 These studies were largely based on NOS activity or NO release that was enriched in "isolated caveolae," sensitive to cholesterol-disrupting drugs that cannot distinguish "rafts" from caveolae or using mutants of eNOS that do not reach the Golgi or plasma membrane. However, at that time, it was virtually impossible to discern cholesterol-rich rafts from caveolae proper, a distinction easily found in cells or mice lacking caveolins. With respect to the inhibitory function of caveolin-1, the putative CSD (amino acids 82 to 101) in caveolin-1, which potentially interacts with many proteins,53 inhibits eNOS activity54–56 by reducing NADPH-dependent electron flux from the reductase to the oxygenase domain of eNOS, thereby reducing NO release from cells.57 Interestingly, delivery of CSD to permeabilized cells52 or cell-permeable versions of CSD can block NO release and inhibit endothelium-dependent responses of isolated blood vessels, inflammation, vascular permeability, angiogenesis, and tumor growth in vivo.58–60 Although genetic data in mice deficient in caveolin-1 (see later) strongly validate the negative regulatory influence of caveolin-1 on eNOS function, a more mechanistic understanding is necessary to fully appreciate how caveolin-1 influences eNOS given the complex regulation of eNOS activity by protein phosphorylation, additional protein–protein interactions, and its cellular trafficking and activation in the Golgi complex of cells.61,62
|
Mechanotransduction |
|---|
|
TopAbstractIntroductionEndothelium: Paradigm Shift From...Caveolae and Signal TransductionRole for Caveolae in...Caveolin-1Endothelial Nitric Oxide...MechanotransductionTyrosine Kinases and Signaling...Caveolins and EC FunctionsCaveolins and VSM FunctionCaveolin-1 and AtherosclerosisCaveolins and Myocardial...ConclusionsReferences |
|---|
Shear stress, the mechanical force sensed by the endothelium initiated by the laminar flow of blood, regulates EC survival versus death decisions, chemokinesis, gene expression, and cytoskeletal remodeling in cultured EC. Because all these cellular responses are secondary to mechanotransduction, ECs are therefore capable of converting physical forces into intracellular signaling events.63
The initial work by Schnitzer suggested that caveolae may act as mechanosensors or transducers.24 This compelling hypothesis is based on evidence that flow-mediated tyrosyl phosphorylation of proteins is markedly enriched in proteins in isolated caveolae versus bulk plasma membrane. Indeed, eNOS activation is enhanced in caveolae isolated from lungs exposed to flow, supporting the concept that mechanosignaling can occur via proteins found in caveolae.64 In cultured EC, shear stress increases net tyrosine phosphorylation and mitogen-activated protein kinase (MAPK) activation, effects reduced by cholesterol-disrupting drugs.65 Caveolae numbers are drastically reduced in cultured EC as compared with in vivo conditions, but most importantly, caveolae density can be at least partly restored by conditioning cells under laminar flow.9,33 Thus, mechanotransduction may occur in caveolae and, in turn, continual shear stress may upregulate de novo formation of the organelle. Extrapolation of these findings to the in vivo setting suggests that chronic shear stress in conduit vessels may regulate caveolae turnover and adjust the number of caveolae in the plasmalemma according to the caliber of the vessel, flow rate, and perceived mean shear stress. Furthermore, wall stress and strain, especially in the vessels exhibiting myogenic tone in the microvasculature, may also initiate signaling via caveolae and regulate arteriolar remodeling. Definitive molecular approaches to dissect this concept will no doubt be forthcoming.
|
Tyrosine Kinases and Signaling Effectors |
|---|
|
TopAbstractIntroductionEndothelium: Paradigm Shift From...Caveolae and Signal TransductionRole for Caveolae in...Caveolin-1Endothelial Nitric Oxide...MechanotransductionTyrosine Kinases and Signaling...Caveolins and EC FunctionsCaveolins and VSM FunctionCaveolin-1 and AtherosclerosisCaveolins and Myocardial...ConclusionsReferences |
|---|
Tyrosine kinases are thought to be regulated by localization in caveolae or by interactions with caveolin-1 in ECs. For instance, in silica-purified caveolae from lung or cultured EC, the nonreceptor tyrosine kinases (lck, fyn, lyn, yes, and src), PI-3 kinase, and the platelet-derived growth factor receptor, some of its downstream effectors, and total tyrosyl phosphorylated proteins66 were enriched in caveolae compared with bulk plasma membrane. The binding of albumin to one of its cognate binding partners, Gp60, triggers an increase tyrosine phosphorylation and protein–protein interactions between caveolin-1, c-src, and fyn in EC, events that presumably take place in caveolae and relate to the transcytosis of albumin.67 More recently, the vascular endothelial growth factor receptor-2 (VEGFR-2), a key player in the induction of physiological and pathological angiogenesis, was shown to be localized in isolated caveolin-enriched membranes and interact with caveolin-1.34,68 Mitogen-activated proteins kinases, Erk 1 and 2, also are found in caveolin-enriched domains or caveolae when cholesterol levels are depleted in fibroblasts69 and may interact with caveolin-1.70 This interaction also appears to attenuate Erk signaling and seems to be bidirectional, because increased Erk activity downregulates caveolin-1 mRNA and protein levels. Such a response may be stimulus-dependent, because shear stress can induce Erk activation and caveolae formation.
In the context of vascular smooth muscle (VSM), angiotensin II signals via the angiotensin II receptor I (AT1R) in caveolae and may transactivate the epidermal growth factor receptor to promote tyrosine kinase signaling leading to cellular proliferation.71 Recent data suggest that caveolin-3 may act as a chaperone for the AT1R, allowing the latter to traffic through the exocytic pathway and to localize at the cell membrane.72 This interaction appears to be mediated by the CSD and is required to prevent the mislocalization of ATIR to lipid bodies or Golgi, which results in aberrant maturation and surface expression of AT1R, effects that are not reversed by supplementing cells with cholesterol.
G-Protein–Coupled Receptors and G-Proteins
Several studies revealed that certain G-protein–coupled receptors (GPCRs) can be found in enriched caveolin-containing membranes assumed to be caveolae, such as endothelin and bradykinin receptors (bradykinin R2).73,74 In addition, the endocytosis of liganded GPCR may occur via caveolae and initiate or terminate signaling.75–78 An example of agonist-stimulated regulation of receptor-effector complexes in caveolin-1–enriched membranes can be illustrated by the bradykinin R2 pathway. In ECs under basal conditions, Tyk2, STAT3, and the bradykinin R2 are localized either partially or entirely in caveolin-1–enriched fractions using sucrose gradient fractionation. After bradykinin stimulation, the bradykinin R2 and STAT3 are translocated out of caveolin-1–enriched membranes, resulting in STAT3 phosphorylation, nuclear translocation, and gene expression.79 Similar results have been shown with other GPCR agonists; however, the molecular mechanisms of ligand-induced movement out of caveolae, receptor-caveolae endocytosis, or the importance of caveolin-1 in these processes are not well-understood.
Evidence also exists for ß-adrenergic receptor 2 (ß2-AR) signaling within caveolae. The ß2-AR can target into caveolae, colocalize, coprecipitate, and coenrich with caveolin-3 in caveolin-3–enriched membrane fractions. Furthermore, dissociation of ß2-AR from caveolin-3 increases downstream G-protein activation by 2-fold.80 Interestingly, caveolin-3 cofractionates with several G-protein subunits such as Gß
, Gi, G2
, and it is believed that such sequestration of G-proteins in caveolae promotes their desensitization by preventing further binding to activated receptors.81,82
Two final examples illustrating agonist-mediated, caveolae-dependent signaling are noteworthy. Carbachol binds to the muscarinic acetylcholine receptors (mAchRs) and stimulates receptor clustering into isolated caveolae.77,83 Stimulation of myocytes with carbachol induced sequestration of mAchRs through caveolae fission. The fission of caveolae was increased by GTP and the protein dynamin and decreased by a nonhydrolyzable GTP and dominant-negative dynamin consistent with previous data showing that dynamin is critical for caveolae internalization.13 Functionally, carbachol-mediated mAchR sequestration and the interaction of caveolin with eNOS was stabilized by dynamin, but not dominant-negative dynamin, suggesting that caveolae fission may contribute to GPCR desensitization. However, a recent report has shown that a nonhydrolyzable GTP analog or expression of dominant-negative dynamin impairs bradykinin-stimulated NO release by preventing the internalization of eNOS-containing vesicles. These 2 studies show the importance of signaling complex recruitment into caveolae and the roles of dynamin-mediated endocytosis in attenuating or enhancing signaling.
The increased concentration of GPCR in caveolae may be ligand-binding–dependent or ligand-binding–independent, and is thought to be an important initial step in the induction of the intracellular signaling events because several downstream transducers are also found in caveolin-1–enriched membranes/caveolae. Interestingly, affinity purification experiments reveal that certain G-proteins (Gq, but not Gi and Gs) are also considerably enriched in isolated ECs caveolae.84 However, the mechanism of how or if caveolins/caveolae regulate G-protein signaling is not well-understood.85,86
Physiological and Pathological Roles of Caveolins in the Vascular System
As illustrated, the roles of caveolae and caveolins in the regulation of many cellular processes in cultured cells are vast; thus, they may be considered by many investigators as essential signaling platforms or, conversely, as unsophisticated cellular glue studied with methodological naiveté. However, in the past few years, development of animal models and the usage of genetically altered mice have been instrumental in deciphering their physiological functions in vivo. Transgenic overexpression of caveolin-1 or caveolin-3 in mice87,88 or the targeted disruption of each of the caveolin gene locus in mice (Cav1, Cav2, and Cav3 genes) has provided significant insights to the roles of the caveolins and caveolae (Table). The initial surprise revealed from the caveolin-1 knockout mice is that they do not exhibit any obvious developmental abnormalities or embryonic lethality;50,51 however, as the get older, they tend to have shorter lifespans.89 Caveolin-1–/– mice show complete ablation of the presence of the caveolae cellular organelle in the endothelia and fat. Similarly, caveolin-3–/– mice lack caveolae in cells that normally express this protein such as skeletal muscle, heart, and the diaphragm.90,91 This demonstrated that caveolins-1 and -3 are necessary for the formation of the caveolae; however, it also indicates that this major cellular organelle is not essential for life. In contrast to caveolin-1 and -3, the loss of caveolin-2 does not prevent the formation of the caveolae, suggesting that this protein is dispensable for the formation of the membrane organelle, although these mice exhibit pulmonary fibrosis.92 Despite the fact that mice deficient in caveolins do not display severe abnormalities, the careful analysis of their phenotypes has generated interesting information on the importance of these proteins in the cardiovascular system.
|
|
Caveolins and EC Functions |
|---|
|
TopAbstractIntroductionEndothelium: Paradigm Shift From...Caveolae and Signal TransductionRole for Caveolae in...Caveolin-1Endothelial Nitric Oxide...MechanotransductionTyrosine Kinases and Signaling...Caveolins and EC FunctionsCaveolins and VSM FunctionCaveolin-1 and AtherosclerosisCaveolins and Myocardial...ConclusionsReferences |
|---|
The first in vivo evidence of a role of caveolin-1 as a negative regulator of signaling molecules through protein–protein interactions was demonstrated based on its interaction with eNOS. As mentioned previously, in vitro experiments showed that caveolin-1 inhibits eNOS activity and NO production via a direct interaction between the CSD and eNOS. The functional evidence of this interaction in vivo was initially revealed by the use of a cell permeable peptide linked to the CSD.58 This peptide was able to internalize into the endothelium, abrogate NO release, and endothelium-dependent vasodilation of isolated blood vessels analogous to a report in permeabilized cultured cardiac myocytes.52 Furthermore, administration of the cell-permeable CSD peptide inhibited NO-dependent vascular permeability, edema, and inflammation in mice.
Interestingly, the initial publications of caveolin-1 null mice also reported that the caveolin-1/eNOS interaction has functional significance.50,51 Isolated aortae from caveolin-1–/– mice exhibited blunted responses to vasoconstrictor agents and also marked increases in vasodilatory responses to the endothelium-dependent vasodilator, acetylcholine, and both these effects were reverted by treatment of the vessels with L-NAME, a NOS inhibitor. These results suggest that the absence of caveolin-1 and caveolae in ECs leads to increased eNOS activity and thus NO release resulting in reduced vascular tone.
The enhanced eNOS activity observed in caveolin-1–/– mice resulted in increased albumin extravasation, which is returned to normal after treatment of mice with the nonspecific NOS inhibitor, L-nitro arginine methyl ester.93 The endothelium of caveolin-1–/– mice lacked transcytotic vesicles typically important for macromolecule exchange and exhibited defects in tight junction density, both attributes that may explain the increased basal permeability. Interestingly, eNOS-derived NO also governs a significant component of the paracellular transport of plasma macromolecules across the endothelium of adult mice because eNOS–/– mice show blunted increases in vascular permeability in response to VEGF.94 In addition, inhibition of eNOS activity using a cell-permeable CSD peptide reduces vascular permeability and edema stimulated by pro-inflammatory agents and VEGF58,59 as well as platelet-activating factor-mediated increases in hydraulic conductivity in isolated postcapillary venules.60 Thus, the genetic loss of caveolin-1 increases basal NO release, which may promote albumin leakage, and blockade of eNOS reduces vascular leakage.
ECs are intimately involved in the regulation of the angiogenic process. The formation of new blood vessels derived from previously established vasculature involves the proliferation, migration, and recruitment of ECs and endothelial progenitors and a role for caveolin-1 in this process have been implicated. Initial experiments examining the effects of caveolin-1 overexpression on endothelial proliferation and differentiation suggested that caveolin-1 is a negative regulator of EC proliferation but promotes cellular differentiation. Adenoviral-mediated overexpression of caveolin-1 significantly enhanced ECs differentiation into tube-like structures and, conversely, downregulation of caveolin-1 protein levels using antisense oligonucleotides reduced the ability of the EC to form an organized network.95 However, angiogenic factors such as VEGF have been shown to induce downregulation of caveolin-1, which was suggested to be important for the mitogenic effects of growth factors in ECs.96 A more definitive role for caveolin-1 in blood vessel formation came from caveolin-1–/– animals. Firstly, caveolin-1 does not seem to be a prerequisite for embryonic vasculogenesis, angiogenesis, or remodeling because these knockout animals develop a normal vasculature. However, postnatal angiogenesis seem to be reduced in caveolin-1 null mice using a growth factor-embedded matrigel assay. Similarly, tumor angiogenesis was also reduced in caveolin–/– mice implanted with B16 melanoma cells.97 These latter results suggest that EC caveolin-1/caveolae is important for the organization of a new capillary network. One must, however, bear in mind that caveolin-1 is an important regulator of eNOS signaling in ECs and that NO is also a major component postnatal angiogenesis. As mentioned previously, NO is essential for VEGF-driven angiogenesis, vascular permeability, and tumor growth.94,98 We recently showed that inhibition of eNOS activity in tumors using the cell-permeable CSD peptide resulted in reduce intratumor vascular leakage and tumor growth, suggesting that caveolin-1–mediated eNOS inhibition is a potential target for antitumor therapy. Moreover, tumors implanted on eNOS–/– mice grew slower and exhibited reduced angiogenesis.59 Overall, one clear phenotype that has emerged from the caveolin-1–/– mice is the importance of caveolin-1 in regulating eNOS function, thus validating the initial work describing this protein–protein interaction. However, the loss of evoked angiogenesis in caveolin-1–/– is more complex and cannot be rationalized via increased eNOS activation unless the loss of caveolae markedly diminishes coupling to eNOS activation.
|
Caveolins and VSM Function |
|---|
|
TopAbstractIntroductionEndothelium: Paradigm Shift From...Caveolae and Signal TransductionRole for Caveolae in...Caveolin-1Endothelial Nitric Oxide...MechanotransductionTyrosine Kinases and Signaling...Caveolins and EC FunctionsCaveolins and VSM FunctionCaveolin-1 and AtherosclerosisCaveolins and Myocardial...ConclusionsReferences |
|---|
As mentioned in the previous section, caveolin-1 and caveolin-3 are present in vascular smooth muscle cells (VSMC),81 with caveolin-1 expressed in arteries and veins and caveolin-3 expressed in arterial but not venous vasculature.99 In addition, caveolae number, per se, and levels of caveolin may be regulated by the phenotypic state of VSM.100–103 However, little is known about the physiological involvement of caveolins in VSMC function. Evidence for a role of caveolin-1 in VSMC-mediated contraction of arteries comes from caveolin-1–/– mice that display reduced myogenic tone.50 Myogenic tone, a critical autoregulatory response found in the microcirculation, is regulated by a feedback mechanism tightly linking spontaneous transient outward currents to local Ca2+ increases in the adjacent sarcoplasmic reticulum. These 2 events have been suggested to be dependent on the presence of caveolae.104 Caveolin–/– mice showed reduced spontaneous transient outward currents, a determinant of myogenic tone, indicating that caveolae integrity is necessary for efficient Ca2+ signaling in VSMC, an effect that may be modulated by the hyperactivation of the eNOS pathway, which may increase calcium clearing mechanisms. Recently, chemical loading of contractile VSM tissue with a synthetic caveolin-1 scaffolding domain peptide inhibited protein kinase C–dependent increases in contractility induced by a phorbol ester or an
agonist.105 These results are consistent with a role for caveolin-1 in the coordination of signaling leading to the regulation of contractility of smooth muscle. However, to date, there is no evidence for altered hemodynamics in caveolin-1–/– mice to support these in vitro findings. |
Caveolin-1 and Atherosclerosis |
|---|
|
TopAbstractIntroductionEndothelium: Paradigm Shift From...Caveolae and Signal TransductionRole for Caveolae in...Caveolin-1Endothelial Nitric Oxide...MechanotransductionTyrosine Kinases and Signaling...Caveolins and EC FunctionsCaveolins and VSM FunctionCaveolin-1 and AtherosclerosisCaveolins and Myocardial...ConclusionsReferences |
|---|
Caveolin-1 and caveolae have the propensity to influence atherogenesis in many ways. Caveolin-1 is a cholesterol-binding protein that can transport cholesterol from the endoplasmic reticulum to the plasma membrane,37 and major receptors for high-density lipoprotein, SR-B1, and a scavenger receptor for modified forms of LDL, CD36, can reside in and signal in caveolae-type microdomains.106 In addition, oxidized LDL can extract caveolae cholesterol, mislocalize eNOS, and impair NO release.41 Conversely, blockade of HMG CoA reductase with statin-based drugs reduces caveolin levels and promote eNOS activation.107,108 This concept has been validated in apolipoprotein E-deficient (ApoE–/–) mice when statin treatment decreases caveolin-1 expression and promotes NOS function in vivo.109 However, to date, there are no data showing changes in caveolin-1 levels in atherosclerotic lesions from humans.
To directly test if caveolin-1 influenced lesion progression in mice, the Lisanti group110 bred mice deficient in caveolin-1–/– mice to ApoE–/– mice that develop atheromas. Interestingly, the loss of caveolin-1 in the ApoE–/– background resulted in a proatherogenic lipid profile, similar to that seen in CD36–/– mice bred to an ApoE background.111,112 Surprisingly, despite a pro-atherogenic lipid profile, the loss of caveolin-1 reduced lesion burden by 80%, suggesting caveolin-1 regulated LDL-mediated vascular dysfunction, inflammation, and lesion progression. The authors suggested this may be caused by a decrease in stability of the scavenger receptor for oxidized or modified LDL, CD36 in macrophages, and an increase in endothelium-derived NO production, which would reduce vascular inflammation. These remarkable findings unequivocally support the importance of caveolin-1/caveolae in the pathogenesis of atherosclerosis in mice and stimulate many questions regarding the roles of caveolin-1 in lipid homeostasis.
|
Caveolins and Myocardial Function |
|---|
|
TopAbstractIntroductionEndothelium: Paradigm Shift From...Caveolae and Signal TransductionRole for Caveolae in...Caveolin-1Endothelial Nitric Oxide...MechanotransductionTyrosine Kinases and Signaling...Caveolins and EC FunctionsCaveolins and VSM FunctionCaveolin-1 and AtherosclerosisCaveolins and Myocardial...ConclusionsReferences |
|---|
Caveolin-3 expression, in contrast to caveolin-1 and -2, is mostly confined to striated (cardiac and skeletal) and smooth muscle. Caveolin-3 has been shown in muscle cells to be responsible for organelle biogenesis in these tissues and caveolin-3–/– mice lack the presence of caveolae only in these tissues.90,91 Caveolin-3 is expressed during muscle differentiation and is localized to the sarcolemma, where it indirectly interacts with dystrophin and dystrophin-associated proteins. An alteration in the assembly of the caveolin-3/dystrophin complex either by reduced or increased caveolin-3 expression results in dystrophic condition of the skeletal muscle.87 Also, caveolin-3 is endogenously expressed in cardiac myocytes, where it was suggested to negatively regulated NOS activity.52,113,114 Transgenic overexpression of caveolin-3 results in cardiomyopathy characterized by myocyte degeneration and disorganization. These animals exhibit increased cellular infiltrates, inflammation, and cardiac fibrosis. Cardiac function in these animals is characterized by increase QRS duration but normal heart rate and corrected QT intervals. No evidences of cardiac hypertrophy were observed.88 Interestingly, cardiac NOS activity was significantly reduced without any change in eNOS or nNOS protein levels, suggesting that increased expression of caveolin-3 resulted in tonic inhibition of both isoforms through increased caveolin-3-eNOS/nNOS interaction in the transgenic animals. Because previous evidence suggested a modulatory role of NO in cardiac function,52,115,116 it is tempting to speculate that reduction in NO levels in the caveolin-3 transgenic mice may be responsible, at least in part, for the impaired cardiac function.
In contrast to caveolin-3 overexpression in mice, which does not lead to cardiac hypertrophy, genetic ablation of the Cav-3 gene results in cardiomyopathy but is characterized by significant hypertrophy, dilatation, and reduced cardiac shortening.117 This increase in cardiac mass has been proposed to be a consequence of the hyperactivation of the MAPK cascade, which drives myocyte hypertrophy, suggesting that caveolin-3 is a negative regulator of the p42/44 MAPK and that loss of caveolin-3 expression is sufficient to induce cardiomyopathy. Loss of caveolin-1 expression also results in cardiomyopathy and hypertrophy;118,119 however, because caveolin-1 is not normally expressed in myocytes, the deficiencies of this protein in cardiac fibroblasts119or perhaps ECs118 may contribute to this phenotype in mice. Again, the hyperactivation of the MAPK cascade was associated with observed cardiac hypertrophy. As expected, the genetic loss of both caveolin-1 and -3 also results in severe cardiomyopathy and displays dramatic increases in left ventricular wall thickness, as compared with caveolin-1–/–, caveolin-3–/–, and wild-type mice. As predicted, biochemical markers of hypertrophy such as atrial natriuretic peptide levels were markedly upregulated.120 However, in all these studies, it is still not clear if the alteration in cardiac function cause by modulation of caveolin levels is because of the role of caveolins as a negative regulator of proliferation, hypertrophy, or remodeling by modulating signal transduction (such as ß-adrenergic signaling, NO, and the MAPK cascade), or the result of intrinsic defects within cardiac myocytes caused by structural derangements of the cardiac T-tubule system or impaired calcium homeostasis.121–123
|
Conclusions |
|---|
|
TopAbstractIntroductionEndothelium: Paradigm Shift From...Caveolae and Signal TransductionRole for Caveolae in...Caveolin-1Endothelial Nitric Oxide...MechanotransductionTyrosine Kinases and Signaling...Caveolins and EC FunctionsCaveolins and VSM FunctionCaveolin-1 and AtherosclerosisCaveolins and Myocardial...ConclusionsReferences |
|---|
Caveolae and caveolins are undoubtedly influencing various aspects of the cardiovascular system. Clearly, the loss of caveolin-1 is having a profound effect on the eNOS pathway, indicating the prominence of this important interaction, whereas the loss of caveolin-3 impacts NOS as well as MAPK activation. Considering the caveats associated with caveolae isolation and their biochemistry, and the growing number of potential of targets that may exist in isolated caveolae, much more work is required in vivo to dissect which signaling pathways are "in or out" of caveolae in a more meaningful way.
|
Acknowledgments |
|---|
This work is supported by grants from the National Institutes of Health (RO1 HL57665, HL61371, HL64793 to W.C.S.). P.B. is a recipient of a fellowship from the Canadian Institutes of Health Research. The authors apologize for citing reviews and only key references because of space limitations.
|
Footnotes |
|---|
*Both authors contributed equally to this work.
Original received December 12, 2003; revision received April 8, 2004; accepted April 12, 2004.
|
References |
|---|
|
TopAbstractIntroductionEndothelium: Paradigm Shift From...Caveolae and Signal TransductionRole for Caveolae in...Caveolin-1Endothelial Nitric Oxide...MechanotransductionTyrosine Kinases and Signaling...Caveolins and EC FunctionsCaveolins and VSM FunctionCaveolin-1 and AtherosclerosisCaveolins and Myocardial...ConclusionsReferences |
|---|
1. Stan RV. Structure and function of endothelial caveolae. Microsc Res Tech. 2002; 57: 350–364.[CrossRef][Medline] [Order article via Infotrieve]
2. Munro S. Lipid rafts: elusive or illusive? Cell. 2003; 115: 377–388.[CrossRef][Medline] [Order article via Infotrieve]
3. Parton RG, Richards AA. Lipid rafts and caveolae as portals for endocytosis: new insights and common mechanisms. Traffic. 2003; 4: 724–738.[CrossRef][Medline] [Order article via Infotrieve]
4. Carver LA, Schnitzer JE. Caveolae: mining little caves for new cancer targets. Nat Rev Cancer. 2003; 3: 571–581.[CrossRef][Medline] [Order article via Infotrieve]
5. Razani B, Woodman SE, Lisanti MP. Caveolae: from cell biology to animal physiology. Pharmacol Rev. 2002; 54: 431–467.
6. Dvorak AM, Feng D. The vesiculo-vacuolar organelle (VVO). A new endothelial cell permeability organelle. J Histochem Cytochem. 2001; 49: 419–432.
7. Schnitzer JE, Siflinger-Birnboim A, Del Vecchio PJ, Malik AB. Segmental differentiation of permeability, protein glycosylation, and morphology of cultured bovine lung vascular endothelium. Biochem Biophys Res Commun. 1994; 199: 11–19.[CrossRef][Medline] [Order article via Infotrieve]
8. Peterson TE, Poppa V, Ueba H, Wu A, Yan C, Berk BC. Opposing effects of reactive oxygen species and cholesterol on endothelial nitric oxide synthase and endothelial cell caveolae. Circ Res. 1999; 85: 29–37.
9. Park H, Go YM, St John PL, Maland MC, Lisanti MP, Abrahamson DR, Jo H. Plasma membrane cholesterol is a key molecule in shear stress-dependent activation of extracellular signal-regulated kinase. J Biol Chem. 1998; 273: 32304–32311.
10. Boyd NL, Park H, Yi H, Boo YC, Sorescu GP, Sykes M, Jo H. Chronic shear induces caveolae formation and alters ERK and Akt responses in endothelial cells. Am J Physiol Heart Circ Physiol. 2003; 285: H1113–H1122.
11. Simionescu M, Simionescu N, Palade GE. Morphometric data on the endothelium of blood capillaries. J Cell Biol. 1974; 60: 128–152.
12. Stewart PA. Endothelial vesicles in the blood-brain barrier: are they related to permeability? Cell Mol Neurobiol. 2000; 20: 149–163.[CrossRef][Medline] [Order article via Infotrieve]
13. Schnitzer JE, Oh P, McIntosh DP. Role of GTP hydrolysis in fission of caveolae directly from plasma membranes. Science. 1996; 274: 239–242.
14. Oh P, McIntosh DP, Schnitzer JE. Dynamin at the neck of caveolae mediates their budding to form transport vesicles by GTP-driven fission from the plasma membrane of endothelium. J Cell Biol. 1998; 141: 101–114.
15. Pelkmans L, Kartenbeck J, Helenius A. Caveolar endocytosis of simian virus 40 reveals a new two-step vesicular-transport pathway to the ER. Nat Cell Biol. 2001; 3: 473–483.[CrossRef][Medline] [Order article via Infotrieve]
16. Severs NJ. Caveolae: static in pocketings of the plasma membrane, dynamic vesicles or plain artifact? J Cell Sci. 1988; 90: 341–348.
17. van Deurs B, Roepstorff K, Hommelgaard AM, Sandvig K. Caveolae: anchored, multifunctional platforms in the lipid ocean. Trends Cell Biol. 2003; 13: 92–100.[CrossRef][Medline] [Order article via Infotrieve]
18. Foster LJ, De Hoog CL, Mann M. Unbiased quantitative proteomics of lipid rafts reveals high specificity for signaling factors. Proc Natl Acad Sci U S A. 2003; 100: 5813–5818.
19. Razani B, Lisanti MP. Caveolin-deficient mice: insights into caveolar function human disease. J Clin Invest. 2001; 108: 1553–1561.[CrossRef][Medline] [Order article via Infotrieve]
20. Sargiacomo M, Sudol M, Tang Z, Lisanti MP. Signal transducing molecules and glycosyl-phosphatidylinositol-linked proteins form a caveolin-rich insoluble complex in MDCK cells. J Cell Biol. 1993; 122: 789–807.
21. Monier S, Parton RG, Vogel F, Behlke J, Henske A, Kurzchalia TV. VIP21-caveolin, a membrane protein constituent of the caveolar coat, oligomerizes in vivo and in vitro. Mol Biol Cell. 1995; 6: 911–927.[Abstract]
22. Smart EJ, Ying YS, Mineo C, Anderson RG. A detergent-free method for purifying caveolae membrane from tissue culture cells. Proc Natl Acad Sci U S A. 1995; 92: 10104–10108.
23. Song KS, Li S, Okamoto T, Quilliam LA, Sargiacomo M, Lisanti MP. Co-purification and direct interaction of Ras with caveolin, an integral membrane protein of caveolae microdomains. Detergent-free purification of caveolae microdomains. J Biol Chem. 1996; 271: 9690–9697.
24. Schnitzer JE, Oh P, Jacobson BS, Dvorak AM. Caveolae from luminal plasmalemma of rat lung endothelium: microdomains enriched in caveolin, Ca(2+)-ATPase, and inositol trisphosphate receptor. Proc Natl Acad Sci U S A. 1995; 92: 1759–1763.
25. von Haller PD, Donohoe S, Goodlett DR, Aebersold R, Watts JD. Mass spectrometric characterization of proteins extracted from Jurkat T cell detergent-resistant membrane domains. Proteomics. 2001; 1: 1010–1021.[CrossRef][Medline] [Order article via Infotrieve]
26. Liu P, Rudick M, Anderson RG. Multiple functions of caveolin-1. J Biol Chem. 2002; 277: 41295–41298.
27. Michel CC, Curry FE. Microvascular permeability. Physiol Rev. 1999; 79: 703–761.
28. Minshall RD, Tiruppathi C, Vogel SM, Malik AB. Vesicle formation and trafficking in endothelial cells and regulation of endothelial barrier function. Histochem Cell Biol. 2002; 117: 105–112.[CrossRef][Medline] [Order article via Infotrieve]
29. McIntosh DP, Tan XY, Oh P, Schnitzer JE. Targeting endothelium and its dynamic caveolae for tissue-specific transcytosis in vivo: a pathway to overcome cell barriers to drug and gene delivery. Proc Natl Acad Sci U S A. 2002; 99: 1996–2001.
30. Okamoto T, Schlegel A, Scherer PE, Lisanti MP. Caveolins, a family of scaffolding proteins for organizing "preassembled signaling complexes" at the plasma membrane. J Biol Chem. 1998; 273: 5419–5422.
31. Vepa S, Scribner WM, Natarajan V. Activation of protein phosphorylation by oxidants in vascular endothelial cells: identification of tyrosine phosphorylation of caveolin. Free Radic Biol Med. 1997; 22: 25–35.[CrossRef][Medline] [Order article via Infotrieve]
32. Volonte D, Galbiati F, Pestell RG, Lisanti MP. Cellular stress induces the tyrosine phosphorylation of caveolin-1 (Tyr(14)) via activation of p38 mitogen-activated protein kinase and c-Src kinase. Evidence for caveolae, the actin cytoskeleton, and focal adhesions as mechanical sensors of osmotic stress. J Biol Chem. 2001; 276: 8094–8103.
33. Rizzo V, Morton C, DePaola N, Schnitzer JE, Davies PF. Recruitment of endothelial caveolae into mechanotransduction pathways by flow conditioning in vitro. Am J Physiol Heart Circ Physiol. 2003; 285: H1720–H1729.
34. Labrecque L, Royal I, Surprenant DS, Patterson C, Gingras D, Beliveau R. Regulation of vascular endothelial growth factor receptor-2 activity by caveolin-1 and plasma membrane cholesterol. Mol Biol Cell. 2003; 14: 334–347.
35. Lee H, Park DS, Wang XB, Scherer PE, Schwartz PE, Lisanti MP. Src-induced phosphorylation of caveolin-2 on tyrosine 19. Phospho-caveolin-2 (Tyr(P)19) is localized near focal adhesions, remains associated with lipid rafts/caveolae, but no longer forms a high molecular mass hetero-oligomer with caveolin-1. J Biol Chem. 2002; 277: 34556–34567.
36. Sowa G, Pypaert M, Fulton D, Sessa WC. The phosphorylation of caveolin-2 on serines 23 and 36 modulates caveolin-1-dependent caveolae formation. Proc Natl Acad Sci U S A. 2003; 100: 6511–6516.
37. Murata M, Peranen J, Schreiner R, Wieland F, Kurzchalia TV, Simons K. VIP21/caveolin is a cholesterol-binding protein. Proc Natl Acad Sci U S A. 1995; 92: 10339–10343.
38. Uittenbogaard A, Shaul PW, Yuhanna IS, Blair A, Smart EJ. High density lipoprotein prevents oxidized low density lipoprotein-induced inhibition of endothelial nitric-oxide synthase localization and activation in caveolae. J Biol Chem. 2000; 275: 11278–11283.
39. Uittenbogaard A, Everson WV, Matveev SV, Smart EJ. Cholesteryl ester is transported from caveolae to internal membranes as part of a caveolin-annexin II lipid-protein complex. J Biol Chem. 2002; 277: 4925–4931.
40. Everson WV, Smart EJ. Influence of caveolin, cholesterol, and lipoproteins on nitric oxide synthase: implications for vascular disease. Trends Cardiovasc Med. 2001; 11: 246–250.[CrossRef][Medline] [Order article via Infotrieve]
41. Blair A, Shaul PW, Yuhanna IS, Conrad PA, Smart EJ. Oxidized low density lipoprotein displaces endothelial nitric-oxide synthase (eNOS) from plasmalemmal caveolae and impairs eNOS activation. J Biol Chem. 1999; 274: 32512–32519.
42. Fielding CJ, Fielding PE. Cellular cholesterol efflux. Biochim Biophys Acta. 2001; 1533: 175–189.[Medline] [Order article via Infotrieve]
43. Garcia-Cardena G, Oh P, Liu J, Schnitzer JE, Sessa WC. Targeting of nitric oxide synthase to endothelial cell caveolae via palmitoylation: implications for nitric oxide signaling. Proc Natl Acad Sci U S A. 1996; 93: 6448–6453.
44. Shaul PW, Smart EJ, Robinson LJ, German Z, Yuhanna IS, Ying Y, Anderson RG, Michel T. Acylation targets endothelial nitric-oxide synthase to plasmalemmal caveolae. J Biol Chem. 1996; 271: 6518–6522.
45. Liu J, Sessa WC. Identification of covalently bound amino-terminal myristic acid in endothelial nitric oxide synthase. J Biol Chem. 1994; 269: 11691–11694.
46. Liu J, Garcia-Cardena G, Sessa WC. Biosynthesis and palmitoylation of endothelial nitric oxide synthase: mutagenesis of palmitoylation sites, cysteines-15 and/or -26, argues against depalmitoylation-induced translocation of the enzyme. Biochemistry. 1995; 34: 12333–12340.[CrossRef][Medline] [Order article via Infotrieve]
47. Liu J, Garcia-Cardena G, Sessa WC. Palmitoylation of endothelial nitric oxide synthase is necessary for optimal stimulated release of nitric oxide: implications for caveolae localization. Biochemistry. 1996; 35: 13277–13281.[CrossRef][Medline] [Order article via Infotrieve]
48. Liu J, Hughes TE, Sessa WC. The first 35 amino acids and fatty acylation sites determine the molecular targeting of endothelial nitric oxide synthase into the Golgi region of cells: a green fluorescent protein study. J Cell Biol. 1997; 137: 1525–1535.
49. Sowa G, Pypaert M, Sessa WC. Distinction between signaling mechanisms in lipid rafts vs. caveolae. Proc Natl Acad Sci U S A. 2001; 98: 14072–14077.
50. Drab M, Verkade P, Elger M, Kasper M, Lohn M, Lauterbach B, Menne J, Lindschau C, Mende F, Luft FC, Schedl A, Haller H, Kurzchalia TV. Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolin-1 gene-disrupted mice. Science. 2001; 293: 2449–2452.
51. Razani B, Engelman JA, Wang XB, Schubert W, Zhang XL, Marks CB, Macaluso F, Russell RG, Li M, Pestell RG, Di Vizio D, Hou H, Jr., Kneitz B, Lagaud G, Christ GJ, Edelmann W, Lisanti MP. Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities. J Biol Chem. 2001; 276: 38121–38138.
52. Feron O, Dessy C, Opel DJ, Arstall MA, Kelly RA, Michel T. Modulation of the endothelial nitric-oxide synthase-caveolin interaction in cardiac myocytes. Implications for the autonomic regulation of heart rate. J Biol Chem. 1998; 273: 30249–30254.
53. Smart EJ, Graf GA, McNiven MA, Sessa WC, Engelman JA, Scherer PE, Okamoto T, Lisanti MP. Caveolins, liquid-ordered domains, and signal transduction. Mol Cell Biol. 1999; 19: 7289–7304.
54. Garcia-Cardena G, Martasek P, Masters BS, Skidd PM, Couet J, Li S, Lisanti MP, Sessa WC. Dissecting the interaction between nitric oxide synthase (NOS) and caveolin. Functional significance of the nos caveolin binding domain in vivo. J Biol Chem. 1997; 272: 25437–25440.
55. Ju H, Zou R, Venema VJ, Venema RC. Direct interaction of endothelial nitric-oxide synthase and caveolin-1 inhibits synthase activity. J Biol Chem. 1997; 272: 18522–18525.
56. Michel JB, Feron O, Sase K, Prabhakar P, Michel T. Caveolin versus calmodulin. Counterbalancing allosteric modulators of endothelial nitric oxide synthase. J Biol Chem. 1997; 272: 25907–25912.
57. Ghosh S, Gachhui R, Crooks C, Wu C, Lisanti MP, Stuehr DJ. Interaction between caveolin-1 and the reductase domain of endothelial nitric-oxide synthase. Consequences for catalysis. J Biol Chem. 1998; 273: 22267–22271.
58. Bucci M, Gratton JP, Rudic RD, Acevedo L, Roviezzo F, Cirino G, Sessa WC. In vivo delivery of the caveolin-1 scaffolding domain inhibits nitric oxide synthesis and reduces inflammation. Nat Med. 2000; 6: 1362–1367.[CrossRef][Medline] [Order article via Infotrieve]
59. Gratton JP, Lin MI, Yu J, Weiss ED, Jiang ZL, Fairchild TA, Iwakiri Y, Groszmann R, Claffey KP, Cheng YC, Sessa WC. Selective inhibition of tumor microvascular permeability by cavtratin blocks tumor progression in mice. Cancer Cell. 2003; 4: 31–39.[CrossRef][Medline] [Order article via Infotrieve]
60. Zhu L, Schwegler-Berry D, Castranova V, He P. Internalization of caveolin-1 scaffolding domain facilitated by Antennapedia homeodomain attenuates PAF-induced increase in microvessel permeability. Am J Physiol Heart Circ Physiol. 2003; 28: H195–H201.
61. Brouet A, Sonveaux P, Dessy C, Balligand JL, Feron O. Hsp90 ensures the transition from the early Ca2+-dependent to the late phosphorylation-dependent activation of the endothelial nitric-oxide synthase in vascular endothelial growth factor-exposed endothelial cells. J Biol Chem. 2001; 276: 32663–32669.
62. Fulton D, Gratton JP, Sessa WC. Post-translational control of endothelial nitric oxide synthase: why isn’t calcium/calmodulin enough? J Pharmacol Exp Ther. 2001; 299: 818–824.
63. Davies PF, Polacek DC, Shi C, Helmke BP. The convergence of haemodynamics, genomics, and endothelial structure in studies of the focal origin of atherosclerosis. Biorheology. 2002; 39: 299–306.[Medline] [Order article via Infotrieve]
64. Rizzo V, McIntosh DP, Oh P, Schnitzer JE. In situ flow activates endothelial nitric oxide synthase in luminal caveolae of endothelium with rapid caveolin dissociation and calmodulin association. J Biol Chem. 1998; 273: 34724–34729.
65. Rizzo V, Sung A, Oh P, Schnitzer JE. Rapid mechanotransduction in situ at the luminal cell surface of vascular endothelium and its caveolae. J Biol Chem. 1998; 273: 26323–26329.
66. Liu J, Oh P, Horner T, Rogers RA, Schnitzer JE. Organized endothelial cell surface signal transduction in caveolae distinct from glycosylphosphatidylinositol-anchored protein microdomains. J Biol Chem. 1997; 272: 7211–7222.
67. Tiruppathi C, Song W, Bergenfeldt M, Sass P, Malik AB. Gp60 activation mediates albumin transcytosis in endothelial cells by tyrosine kinase-dependent pathway. J Biol Chem. 1997; 272: 25968–25975.
68. Feng Y, Venema VJ, Venema RC, Tsai N, Behzadian MA, Caldwell RB. VEGF-induced permeability increase is mediated by caveolae. Invest Ophthalmol Vis Sci. 1999; 40: 157–167.
69. Furuchi T, Anderson RG. Cholesterol depletion of caveolae causes hyperactivation of extracellular signal-related kinase (ERK). J Biol Chem. 1998; 273: 21099–21104.
70. Engelman JA, Chu C, Lin A, Jo H, Ikezu T, Okamoto T, Kohtz DS, Lisanti MP. Caveolin-mediated regulation of signaling along the p42/44 MAP kinase cascade in vivo. A role for the caveolin-scaffolding domain. FEBS Lett. 1998; 428: 205–211.[CrossRef][Medline] [Order article via Infotrieve]
71. Ushio-Fukai M, Hilenski L, Santanam N, Becker PL, Ma Y, Griendling KK, Alexander RW. Cholesterol depletion inhibits epidermal growth factor receptor transactivation by angiotensin II in vascular smooth muscle cells: role of cholesterol-rich microdomains and focal adhesions in angiotensin II signaling. J Biol Chem. 2001; 276: 48269–48275.
72. Wyse BD, Prior IA, Qian H, Morrow IC, Nixon S, Muncke C, Kurzchalia TV, Thomas WG, Parton RG, Hancock JF. Caveolin interacts with the angiotensin II type 1 receptor during exocytic transport but not at the plasma membrane. J Biol Chem. 2003; 278: 23738–23746.
73. Chun M, Liyanage UK, Lisanti MP, Lodish HF. Signal transduction of a G protein-coupled receptor in caveolae: colocalization of endothelin and its receptor with caveolin. Proc Natl Acad Sci U S A. 1994; 91: 11728–11732.
74. de Weerd WF, Leeb-Lundberg LM. Bradykinin sequesters B2 bradykinin receptors and the receptor-coupled Galpha subunits Galphaq and Galphai in caveolae in DDT1 MF-2 smooth muscle cells. J Biol Chem. 1997; 272: 17858–17866.
75. Escriche M, Burgueno J, Ciruela F, Canela EI, Mallol J, Enrich C, Lluis C, Franco R. Ligand-induced caveolae-mediated internalization of A1 adenosine receptors: morphological evidence of endosomal sorting and receptor recycling. Exp Cell Res. 2003; 285: 72–90.[CrossRef][Medline] [Order article via Infotrieve]
76. Rapacciuolo A, Suvarna S, Barki-Harrington L, Luttrell LM, Cong M, Lefkowitz RJ, Rockman HA. Protein kinase A and G protein-coupled receptor kinase phosphorylation mediates beta-1 adrenergic receptor endocytosis through different pathways. J Biol Chem. 2003; 278: 35403–35411.
77. Dessy C, Kelly RA, Balligand JL, Feron O. Dynamin mediates caveolar sequestration of muscarinic cholinergic receptors and alteration in NO signaling. EMBO J. 2000; 19: 4272–4280.[CrossRef][Medline] [Order article via Infotrieve]
78. Ostrom RS, Gregorian C, Drenan RM, Xiang Y, Regan JW, Insel PA. Receptor number and caveolar co-localization determine receptor coupling efficiency to adenylyl cyclase. J Biol Chem. 2001; 276: 42063–42069.
79. Ju H, Venema VJ, Liang H, Harris MB, Zou R, Venema RC. Bradykinin activates the Janus-activated kinase/signal transducers and activators of transcription (JAK/STAT) pathway in vascular endothelial cells: localization of JAK/STAT signalling proteins in plasmalemmal caveolae. Biochem J. 2000; 351: 257–264.[CrossRef][Medline] [Order article via Infotrieve]
80. Xiang Y, Rybin VO, Steinberg SF, Kobilka B. Caveolar localization dictates physiologic signaling of beta 2-adrenoceptors in neonatal cardiac myocytes. J Biol Chem. 2002; 277: 34280–34286.
81. Song KS, Scherer PE, Tang Z, Okamoto T, Li S, Chafel M, Chu C, Kohtz DS, Lisanti MP. Expression of caveolin-3 in skeletal, cardiac, and smooth muscle cells. Caveolin-3 is a component of the sarcolemma and co-fractionates with dystrophin and dystrophin-associated glycoproteins. J Biol Chem. 1996; 271: 15160–15165.
82. Murthy KS, Makhlouf GM. Heterologous desensitization mediated by G protein-specific binding to caveolin. J Biol Chem. 2000; 275: 30211–30219.
83. Chatterjee S, Cao S, Peterson TE, Simari RD, Shah V. Inhibition of GTP-dependent vesicle trafficking impairs internalization of plasmalemmal eNOS and cellular nitric oxide production. J Cell Sci. 2003; 116: 3645–3655.
84. Oh P, Schnitzer JE. Segregation of heterotrimeric G proteins in cell surface microdomains. G(q) binds caveolin to concentrate in caveolae, whereas G(i) and G(s) target lipid rafts by default. Mol Biol Cell. 2001; 12: 685–698.
85. Huang C, Hepler JR, Chen LT, Gilman AG, Anderson RG, Mumby SM. Organization of G proteins and adenylyl cyclase at the plasma membrane. Mol Biol Cell. 1997; 8: 2365–2378.
86. Li S, Okamoto T, Chun M, Sargiacomo M, Casanova JE, Hansen SH, Nishimoto I, Lisanti MP. Evidence for a regulated interaction between heterotrimeric G proteins and caveolin. J Biol Chem. 1995; 270: 15693–15701.
87. Galbiati F, Volonte D, Chu JB, Li M, Fine SW, Fu M, Bermudez J, Pedemonte M, Weidenheim KM, Pestell RG, Minetti C, Lisanti MP. Transgenic overexpression of caveolin-3 in skeletal muscle fibers induces a Duchenne-like muscular dystrophy phenotype. Proc Natl Acad Sci U S A. 2000; 97: 9689–9694.
88. Aravamudan B, Volonte D, Ramani R, Gursoy E, Lisanti MP, London B, Galbiati F. Transgenic overexpression of caveolin-3 in the heart induces a cardiomyopathic phenotype. Hum Mol Genet. 2003; 12: 2777–2788.
89. Park DS, Cohen AW, Frank PG, Razani B, Lee H, Williams TM, Chandra M, Shirani J, De Souza AP, Tang B, Jelicks LA, Factor SM, Weiss LM, Tanowitz HB, Lisanti MP. Caveolin-1 null (–/–) mice show dramatic reductions in life span. Biochemistry. 2003; 42: 15124–15131.[CrossRef][Medline] [Order article via Infotrieve]
90. Hagiwara Y, Sasaoka T, Araishi K, Imamura M, Yorifuji H, Nonaka I, Ozawa E, Kikuchi T. Caveolin-3 deficiency causes muscle degeneration in mice. Hum Mol Genet. 2000; 9: 3047–3054.
91. Galbiati F, Engelman JA, Volonte D, Zhang XL, Minetti C, Li M, Hou H, Jr., Kneitz B, Edelmann W, Lisanti MP. Caveolin-3 null mice show a loss of caveolae, changes in the microdomain distribution of the dystrophin-glycoprotein complex, and t-tubule abnormalities. J Biol Chem. 2001; 276: 21425–21433.
92. Razani B, Wang XB, Engelman JA, Battista M, Lagaud G, Zhang XL, Kneitz B, Hou H, Jr., Christ GJ, Edelmann W, Lisanti MP. Caveolin-2-deficient mice show evidence of severe pulmonary dysfunction without disruption of caveolae. Mol Cell Biol. 2002; 22: 2329–2344.
93. Schubert W, Frank PG, Woodman SE, Hyogo H, Cohen DE, Chow CW, Lisanti MP. Microvascular hyperpermeability in caveolin-1(–/–) knock-out mice. Treatment with a specific nitric-oxide synthase inhibitor, L-name, restores normal microvascular permeability in Cav-1 null mice. J Biol Chem. 2002; 277: 40091–40098.
94. Fukumura D, Gohongi T, Kadambi A, Izumi Y, Ang J, Yun CO, Buerk DG, Huang PL, Jain RK. Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability. Proc Natl Acad Sci U S A. 2001; 98: 2604–2609.
95. Liu J, Wang XB, Park DS, Lisanti MP. Caveolin-1 expression enhances endothelial capillary tubule formation. J Biol Chem. 2002; 277: 10661–10668.
96. Liu J, Razani B, Tang S, Terman BI, Ware JA, Lisanti MP. Angiogenesis activators and inhibitors differentially regulate caveolin-1 expression and caveolae formation in vascular endothelial cells. Angiogenesis inhibitors block vascular endothelial growth factor-induced down-regulation of caveolin-1. J Biol Chem. 1999; 274: 15781–15785.
97. Woodman SE, Ashton AW, Schubert W, Lee H, Williams TM, Medina FA, Wyckoff JB, Combs TP, Lisanti MP. Caveolin-1 knockout mice show an impaired angiogenic response to exogenous stimuli. Am J Pathol. 2003; 162: 2059–2068.
98. Murohara T, Asahara T, Silver M, Bauters C, Masuda H, Kalka C, Kearney M, Chen D, Symes JF, Fishman MC, Huang PL, Isner JM. Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. J Clin Invest. 1998; 101: 2567–2578.[Medline] [Order article via Infotrieve]
99. Segal SS, Brett SE, Sessa WC. Codistribution of NOS and caveolin throughout peripheral vasculature and skeletal muscle of hamsters. Am J Physiol. 1999; 277: H1167–H1177.[Medline] [Order article via Infotrieve]
100. Thyberg J, Roy J, Tran PK, Blomgren K, Dumitrescu A, Hedin U. Expression of caveolae on the surface of rat arterial smooth muscle cells is dependent on the phenotypic state of the cells. Lab Invest. 1997; 77: 93–101.[Medline] [Order article via Infotrieve]
101. Thyberg J. Caveolae and cholesterol distribution in vascular smooth muscle cells of different phenotypes. J Histochem Cytochem. 2002; 50: 185–195.
102. Thyberg J. Caveolin-1 and caveolae act as regulators of mitogenic signaling in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2003; 23: 1481–1483.
103. Peterson TE, Guicciardi ME, Gulati R, Kleppe LS, Mueske CS, Mookadam M, Sowa G, Gores GJ, Sessa WC, Simari RD. Caveolin-1 can regulate vascular smooth muscle cell fate by switching platelet-derived growth factor signaling from a proliferative to an apoptotic pathway. Arterioscler Thromb Vasc Biol. 2003; 23: 1521–1527.
104. Lohn M, Furstenau M, Sagach V, Elger M, Schulze W, Luft FC, Haller H, Gollasch M. Ignition of calcium sparks in arterial and cardiac muscle through caveolae. Circ Res. 2000; 87: 1034–1039.
105. Je HD, Gallant C, Leavis PC, Morgan KG. Caveolin-1 Regulates Contractility in Differentiated Vascular Smooth Muscle. Am J Physiol Heart Circ Physiol. 2003; 286: H91–H8.[Medline] [Order article via Infotrieve]
106. Graf GA, Matveev SV, Smart EJ. Class B scavenger receptors, caveolae and cholesterol homeostasis. Trends Cardiovasc Med. 1999; 9: 221–225.[CrossRef][Medline] [Order article via Infotrieve]
107. Feron O, Dessy C, Desager JP, Balligand JL. Hydroxy-methylglutaryl-coenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance. Circulation. 2001; 103: 113–118.
108. Brouet A, Sonveaux P, Dessy C, Moniotte S, Balligand JL, Feron O. Hsp90 and caveolin are key targets for the proangiogenic nitric oxide-mediated effects of statins. Circ Res. 2001; 89: 866–873.
109. Pelat M, Dessy C, Massion P, Desager JP, Feron O, Balligand JL. Rosuvastatin decreases caveolin-1 and improves nitric oxide-dependent heart rate and blood pressure variability in apolipoprotein E–/– mice in vivo. Circulation. 2003; 107: 2480–2486.
110. Frank PG, Lee H, Park DS, Tandon NN, Scherer PE, Lisanti MP. Genetic ablation of caveolin-1 confers protection against atherosclerosis. Arterioscler Thromb Vasc Biol. 2003; 24: 98–105.
111. Febbraio M, Podrez EA, Smith JD, Hajjar DP, Hazen SL, Hoff HF, Sharma K, Silverstein RL. Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. J Clin Invest. 2000; 105: 1049–1056.[Medline] [Order article via Infotrieve]
112. Podrez EA, Febbraio M, Sheibani N, Schmitt D, Silverstein RL, Hajjar DP, Cohen PA, Frazier WA, Hoff HF, Hazen SL. Macrophage scavenger receptor CD36 is the major receptor for LDL modified by monocyte-generated reactive nitrogen species. J Clin Invest. 2000; 105: 1095–1108.[Medline] [Order article via Infotrieve]
113. Feron O, Belhassen L, Kobzik L, Smith TW, Kelly RA, Michel T. Endothelial nitric oxide synthase targeting to caveolae. Specific interactions with caveolin isoforms in cardiac myocytes and endothelial cells. J Biol Chem. 1996; 271: 22810–22814.
114. Venema VJ, Ju H, Zou R, Venema RC. Interaction of neuronal nitric-oxide synthase with caveolin-3 in skeletal muscle. Identification of a novel caveolin scaffolding/inhibitory domain. J Biol Chem. 1997; 272: 28187–28190.
115. Barouch LA, Harrison RW, Skaf MW, Rosas GO, Cappola TP, Kobeissi ZA, Hobai IA, Lemmon CA, Burnett AL, O’Rourke B, Rodriguez ER, Huang PL, Lima JA, Berkowitz DE, Hare JM. Nitric oxide regulates the heart by spatial confinement of nitric oxide synthase isoforms. Nature. 2002; 416: 337–339.[Medline] [Order article via Infotrieve]
116. Massion PB, Balligand JL. Modulation of cardiac contraction, relaxation and rate by the endothelial nitric oxide synthase (eNOS): lessons from genetically modified mice. J Physiol. 2003; 546: 63–75.
117. Woodman SE, Park DS, Cohen AW, Cheung MW, Chandra M, Shirani J, Tang B, Jelicks LA, Kitsis RN, Christ GJ, Factor SM, Tanowitz HB, Lisanti MP. Caveolin-3 knock-out mice develop a progressive cardiomyopathy and show hyperactivation of the p42/44 MAPK cascade. J Biol Chem. 2002; 277: 38988–38997.
118. Zhao YY, Liu Y, Stan RV, Fan L, Gu Y, Dalton N, Chu PH, Peterson K, Ross J, Jr., Chien KR. Defects in caveolin-1 cause dilated cardiomyopathy and pulmonary hypertension in knockout mice. Proc Natl Acad Sci U S A. 2002; 99: 11375–11380.
119. Cohen AW, Park DS, Woodman SE, Williams TM, Chandra M, Shirani J, Pereira de Souza A, Kitsis RN, Russell RG, Weiss LM, Tang B, Jelicks LA, Factor SM, Shtutin V, Tanowitz HB, Lisanti MP. Caveolin-1 null mice develop cardiac hypertrophy with hyperactivation of p42/44 MAP kinase in cardiac fibroblasts. Am J Physiol Cell Physiol. 2003; 284: C457–C474.
120. Park DS, Woodman SE, Schubert W, Cohen AW, Frank PG, Chandra M, Shirani J, Razani B, Tang B, Jelicks LA, Factor SM, Weiss LM, Tanowitz HB, Lisanti MP. Caveolin-1/3 double-knockout mice are viable, but lack both muscle and non-muscle caveolae, and develop a severe cardiomyopathic phenotype. Am J Pathol. 2002; 160: 2207–2217.
121. Rybin VO, Xu X, Steinberg SF. Activated protein kinase C isoforms target to cardiomyocyte caveolae : stimulation of local protein phosphorylation. Circ Res. 1999; 84: 980–988.
122. Rybin VO, Xu X, Lisanti MP, Steinberg SF. Differential targeting of beta -adrenergic receptor subtypes and adenylyl cyclase to cardiomyocyte caveolae. A mechanism to functionally regulate the cAMP signaling pathway. J Biol Chem. 2000; 275: 41447–41457.
123. Rybin VO, Pak E, Alcott S, Steinberg SF. Developmental changes in beta2-adrenergic receptor signaling in ventricular myocytes: the role of Gi proteins and caveolae microdomains. Mol Pharmacol. 2003; 63: 1338–1348.
This article has been cited by other articles:
 |
|
 |
|
  K. R. Solomon, K. Pelton, K. Boucher, J. Joo, C. Tully, D. Zurakowski, C. P. Schaffner, J. Kim, and M. R. Freeman Ezetimibe Is an Inhibitor of Tumor Angiogenesis Am. J. Pathol., March 1, 2009; 174(3): 1017 - 1026. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Averna, R. Stifanese, R. De Tullio, M. Passalacqua, F. Salamino, S. Pontremoli, and E. Melloni Functional Role of HSP90 Complexes with Endothelial Nitric-oxide Synthase (eNOS) and Calpain on Nitric Oxide Generation in Endothelial Cells J. Biol. Chem., October 24, 2008; 283(43): 29069 - 29076. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Ogata, T. Ueyama, K. Isodono, M. Tagawa, N. Takehara, T. Kawashima, K. Harada, T. Takahashi, T. Shioi, H. Matsubara, et al. MURC, a Muscle-Restricted Coiled-Coil Protein That Modulates the Rho/ROCK Pathway, Induces Cardiac Dysfunction and Conduction Disturbance Mol. Cell. Biol., May 15, 2008; 28(10): 3424 - 3436. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Ballard-Croft, A. C. Locklar, B. J. Keith, R. M. Mentzer Jr, and R. D. Lasley Oxidative stress and adenosine A1 receptor activation differentially modulate subcellular cardiomyocyte MAPKs Am J Physiol Heart Circ Physiol, January 1, 2008; 294(1): H263 - H271. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Mendez-Bolaina, J. Sanchez-Gonzalez, I. Ramirez-Sanchez, E. Ocharan-Hernandez, M. Nunez-Sanchez, E. Meaney-Mendiolea, A. Meaney, J. Asbun-Bojalil, A. Miliar-Garcia, I. Olivares-Corichi, et al. Effect of caveolin-1 scaffolding peptide and 17 -estradiol on intracellular Ca2+ kinetics evoked by angiotensin II in human vascular smooth muscle cells Am J Physiol Cell Physiol, December 1, 2007; 293(6): C1953 - C1961. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. S. Prakash, M. A. Thompson, B. Vaa, I. Matabdin, T. E. Peterson, T. He, and C. M. Pabelick Caveolins and intracellular calcium regulation in human airway smooth muscle Am J Physiol Lung Cell Mol Physiol, November 1, 2007; 293(5): L1118 - L1126. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Murata, M. I. Lin, Y. Huang, J. Yu, P. M. Bauer, F. J. Giordano, and W. C. Sessa Reexpression of caveolin-1 in endothelium rescues the vascular, cardiac, and pulmonary defects in global caveolin-1 knockout mice J. Exp. Med., October 1, 2007; 204(10): 2373 - 2382. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Yang, C. Ying, M. Xu, X. Zuo, X. Ye, L. Liu, Y. Nara, and X. Sun High-fat diet up-regulates caveolin-1 expression in aorta of diet-induced obese but not in diet-resistant rats Cardiovasc Res, October 1, 2007; 76(1): 167 - 174. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Dumitrescu, R. Biondi, Y. Xia, A. J. Cardounel, L. J. Druhan, G. Ambrosio, and J. L. Zweier Myocardial ischemia results in tetrahydrobiopterin (BH4) oxidation with impaired endothelial function ameliorated by BH4 PNAS, September 18, 2007; 104(38): 15081 - 15086. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. H. Patel, S. Zhang, F. Murray, R. Y. S. Suda, B. P. Head, U. Yokoyama, J. S. Swaney, I. R. Niesman, R. T. Schermuly, S. S. Pullamsetti, et al. Increased smooth muscle cell expression of caveolin-1 and caveolae contribute to the pathophysiology of idiopathic pulmonary arterial hypertension FASEB J, September 1, 2007; 21(11): 2970 - 2979. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Martinez-Ruiz and S. Lamas Signalling by NO-induced protein S-nitrosylation and S-glutathionylation: Convergences and divergences Cardiovasc Res, July 15, 2007; 75(2): 220 - 228. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Kamishima, T. Burdyga, J. A. Gallagher, and J. M. Quayle Caveolin-1 and caveolin-3 regulate Ca2+ homeostasis of single smooth muscle cells from rat cerebral resistance arteries Am J Physiol Heart Circ Physiol, July 1, 2007; 293(1): H204 - H214. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Murata, M. I. Lin, R. V. Stan, P. M. Bauer, J. Yu, and W. C. Sessa Genetic Evidence Supporting Caveolae Microdomain Regulation of Calcium Entry in Endothelial Cells J. Biol. Chem., June 1, 2007; 282(22): 16631 - 16643. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Shmygol, K. Noble, and S. Wray Depletion of membrane cholesterol eliminates the Ca2+-activated component of outward potassium current and decreases membrane capacitance in rat uterine myocytes J. Physiol., June 1, 2007; 581(2): 445 - 456. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Lamalice, F. Le Boeuf, and J. Huot Endothelial Cell Migration During Angiogenesis Circ. Res., March 30, 2007; 100(6): 782 - 794. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. K. Mehta and K. K. Griendling Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system Am J Physiol Cell Physiol, January 1, 2007; 292(1): C82 - C97. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Singleton, S. M. Dudek, S.-F. Ma, and J. G. N. Garcia Transactivation of Sphingosine 1-Phosphate Receptors Is Essential for Vascular Barrier Regulation: NOVEL ROLE FOR HYALURONAN AND CD44 RECEPTOR FAMILY J. Biol. Chem., November 10, 2006; 281(45): 34381 - 34393. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Ushio-Fukai and R. W. Alexander Caveolin-Dependent Angiotensin II Type 1 Receptor Signaling in Vascular Smooth Muscle Hypertension, November 1, 2006; 48(5): 797 - 803. [Full Text] [PDF]
|
|
|
|
|
|
G. Bkaily, P. D'Orleans-Juste, and D. Jacques A New Paradigm: Calcium Independent and Caveolae Internalization Dependent Release of Nitric Oxide by the Endothelial Nitric Oxide Synthase Circ. Res., October 13, 2006; 99(8): 793 - 794. [Full Text] [PDF]
|
|
|
|
|
|
W. P. Schilling, D. Snyder, W. G. Sinkins, and M. Estacion Palytoxin-induced cell death cascade in bovine aortic endothelial cells Am J Physiol Cell Physiol, October 1, 2006; 291(4): C657 - C667. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Mayer Translocation of endothelial nitric oxide synthase: Another feat of amlodipine, a cardiovascular jack-of-all-trades Cardiovasc Res, August 1, 2006; 71(3): 411 - 413. [Full Text] [PDF]
|
|
|
|
|
|
P. G. Frank and M. P. Lisanti Defining lipid raft structure and function with proximity imaging Am J Physiol Heart Circ Physiol, June 1, 2006; 290(6): H2165 - H2166. [Full Text] [PDF]
|
|
|
|
|
|
X. Cheng and J. H. Jaggar Genetic ablation of caveolin-1 modifies Ca2+ spark coupling in murine arterial smooth muscle cells Am J Physiol Heart Circ Physiol, June 1, 2006; 290(6): H2309 - H2319. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. A. Lanzafame, L. Turnbull, F. Amiramahdi, J. F. Arthur, H. Huynh, and E. A. Woodcock Inositol phospholipids localized to caveolae in rat heart are regulated by {alpha}1-adrenergic receptors and by ischemia-reperfusion Am J Physiol Heart Circ Physiol, May 1, 2006; 290(5): H2059 - H2065. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Mukherjee, M. Tessema, and A. Wandinger-Ness Vesicular Trafficking of Tyrosine Kinase Receptors and Associated Proteins in the Regulation of Signaling and Vascular Function Circ. Res., March 31, 2006; 98(6): 743 - 756. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Yang and X.-F. Ming Recent advances in understanding endothelial dysfunction in atherosclerosis. Clin. Med. Res., March 1, 2006; 4(1): 53 - 65. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. D. Hardin and J. Vallejo Caveolins in vascular smooth muscle: Form organizing function Cardiovasc Res, March 1, 2006; 69(4): 808 - 815. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Calaghan and E. White Caveolae modulate excitation-contraction coupling and {beta}2-adrenergic signalling in adult rat ventricular myocytes Cardiovasc Res, March 1, 2006; 69(4): 816 - 824. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Touyz Lipid Rafts Take Center Stage in Endothelial Cell Redox Signaling by Death Receptors Hypertension, January 1, 2006; 47(1): 16 - 18. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Icking, S. Matt, N. Opitz, A. Wiesenthal, W. Muller-Esterl, and K. Schilling NOSTRIN functions as a homotrimeric adaptor protein facilitating internalization of eNOS J. Cell Sci., November 1, 2005; 118(21): 5059 - 5069. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Singleton, S. M. Dudek, E. T. Chiang, and J. G. N. Garcia Regulation of sphingosine 1-phosphate-induced endothelial cytoskeletal rearrangement and barrier enhancement by S1P1 receptor, PI3 kinase, Tiam1/Rac1, and {alpha}-actinin FASEB J, October 1, 2005; 19(12): 1646 - 1656. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Zuo, M. Ushio-Fukai, S. Ikeda, L. Hilenski, N. Patrushev, and R. W. Alexander Caveolin-1 Is Essential for Activation of Rac1 and NAD(P)H Oxidase After Angiotensin II Type 1 Receptor Stimulation in Vascular Smooth Muscle Cells: Role in Redox Signaling and Vascular Hypertrophy Arterioscler. Thromb. Vasc. Biol., September 1, 2005; 25(9): 1824 - 1830. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ikeda, M. Ushio-Fukai, L. Zuo, T. Tojo, S. Dikalov, N. A. Patrushev, and R. W. Alexander Novel Role of ARF6 in Vascular Endothelial Growth Factor-Induced Signaling and Angiogenesis Circ. Res., March 4, 2005; 96(4): 467 - 475. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. N. Bernatchez, P. M. Bauer, J. Yu, J. S. Prendergast, P. He, and W. C. Sessa Dissecting the molecular control of endothelial NO synthase by caveolin-1 using cell-permeable peptides PNAS, January 18, 2005; 102(3): 761 - 766. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. NAVARRO, B. ANAND-APTE, and M.-O. PARAT A role for caveolae in cell migration FASEB J, December 1, 2004; 18(15): 1801 - 1811. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||